The role of tazarotene in the treatment of psoriasis

British Journal of Dermatology, Supplement

Volumn 140, Issue 54, 1999, Pages 24-28

  Marks, Ronald ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Efficacy; Pharmacokinetics; Psoriasis; Retinoid; Safety; Tazarotene

Indexed keywords

FLUOCINONIDE; TAZAROTENE;

CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HYDROPHILICITY; KERATINOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

EID: 0032928715     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.140s54024.x     Document Type: Conference Paper

References (20)

1. Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123-6.
2. McMichael AJ, Griffiths CEM, Talwar HS et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996; 135: 60-4.
3. Lea AP, Goa KL. Calcipotriol. A review of its pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother 1996; 5: 230-48.
4. Bourke JF, Mumford R, Whittaker P et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997; 37: 929-34.
5. Dwyer C, Chapman RS. Calcipotriol and hypercalcaemia. The Lancet 1991; 338: 764-5.
6. MacDonald A, McMinn RMH, Fry L. Effect of retinoic acid in psoriasis, II. Long term study. Br J Dermatol 1972; 87: 256-60.
7. Orfanos CE, Schmidt HW, Mahrle G et al. Retinoic acid in psoriasis: its value for topical therapy with and without corticosteroids. Clinical, histological and electron microscopical studies on 44 hospitalized patients with extensive psoriasis. Br J Dermatol 1973; 88: 167-82.
8. Günther S. The therapeutic value of retinoic acid in chronic discoid, acute guttate, and erythrodermic psoriasis: clinical observations on 25 patients. Br J Dermatol 1973; 89: 515-17.
9. Bischoff R, de Jong EMGJ. Rulo HFC et al. Topical application of 13-cis-retinoic acid in the treatment of chronic plaque psoriasis. Clin Exp Dermatol 1992; 17: 9-12.
10. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA et al. Response of psoriasis to a new topical retinoid. AGN 190168. J Am Acad Dermatol 1994; 30: 581-90.
11. Nagpal S, Thacher SM, Patel S et al. Negative regulation of two hyperproliferative keratinocyte differential ion markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth & Differentiation 1996; 7: 1783-91.
12. Duvic M, Nagpal S, Asano AT, Chandraratna RAS. Molecular mechanisms of tazarotene action in psoriasis, J Am Acad Dermatol 1997; 37: S18-S24.
13. Franz TJ, Lehman PA, Franz S et al. Percutaneous absorption of AGN 190168, a new synthetic retinoid, through human skin invivo. Clin Res 1992; 40: 533A. (Abstract).
14. Tang-Liu DD-S, Matsumoto R, Usansky J. Clinical pharmacokinetics and drug metabolism of tazarotenc, a novel topical retinoid. Clin Pharmacokinetics 1999; in press.
15. Tazarotene product labelling.
16. Chandraratna RAS. Tazarotene - first of a new generation of receptor-selective retinoids, Br J Dermatol 1996; 135 (Suppl. 49); 18-25.
17. Mills CM, Marks R. Adverse reactions to oral retinoids. An update. Drug Safety 1993; 9: 280-90.
18. Geiger J-M, Baudin M, Saurat J-H. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109-16.
19. Weinstein GD, Kreuger GG, Lowe NJ. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85-92.
20. Lebwohl M, Ast E, Callen JP et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38: 705-11.